Agomab Therapeutics NV Adrs (AGMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | |
| Operating Expenses | 67,064 | 51,964 |
| Operating Income | -67,064 | -51,964 |
| Interest Expense | 151 | 386 |
| Other Income | -3,552 | 2,289 |
| Pre-tax Income | -70,766 | -50,061 |
| Income Tax | N/A | 4 |
| Net Income Continuous | -70,766 | -50,066 |
| Net Income | $-70,766 | $-50,066 |
| EPS Basic Total Ops | -162.04 | -2.50 |
| EPS Basic Continuous Ops | -130.77 | -2.00 |
| EPS Diluted Total Ops | -162.04 | -2.50 |
| EPS Diluted Continuous Ops | -130.77 | -2.00 |
| EBITDA(a) | $-66,816 | $-51,627 |